Drugs

Effects of GLP-1 Receptor Agonists on Muscle and Bone Health: A Review and Analysis

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated

Abstract

The effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on musculoskeletal health are currently unclear.

  • GLP-1 RAs are commonly prescribed for managing type 2 diabetes and obesity.
  • There is a lack of understanding regarding how GLP-1 RAs influence musculoskeletal health.
  • Further investigation is needed to clarify the relationship between GLP-1 RAs and musculoskeletal outcomes.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Related papers

Nov '22
Folic acid supplements and malaria risk and severity in people using antifolate malaria drugs in affected areas
cited by 30 papers
systematic review
Jun '25
Summary of studies comparing how well GLP-1 receptor agonists work for weight loss
top 10% journal
cited by 5 papers
systematic review
Jun '26
Lung-related side effects linked to GLP-1 receptor agonist medications: a review of respiratory safety concerns
journal article
Oct '25
Tirzepatide treatment for adults with obesity
cited by 3 papers
systematic review
Oct '25
Liraglutide treatment for adults with obesity
cited by 2 papers
systematic review
Mar '26
Different weight loss responses to GLP-1 receptor drugs in adults: A review and combined analysis
top 2% journal
journal article
Oct '25
Semaglutide treatment for adults with obesity
cited by 10 papers
systematic review
May '17
DPP-4 inhibitors and GLP-1 drugs for preventing or delaying type 2 diabetes and related health problems in high-risk people
cited by 27 papers
systematic review

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #54
GLP-1 drugs don't build habits — and that gap is costing patients their results
5 days ago7 studies
issue #53
Semaglutide slowed aging and extended lifespan in older female mice
1 week ago7 studies
issue #52
GLP-1 drugs linked to lower Parkinson's risk in people with type 2 diabetes
2 weeks ago7 studies
issue #51
Semaglutide linked to nearly double the risk of a rare eye condition in people with diabetes
3 weeks ago7 studies
issue #50
A once-daily pill beat placebo on weight loss — and it wasn't semaglutide
4 weeks ago7 studies
issue #49
GLP-1 drugs work even without weight loss — and scientists are finally mapping why
5 weeks ago7 studies
issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
6 weeks ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
7 weeks ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
8 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief